These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36281114)

  • 1. Ustekinumab is effective against ulcerative colitis with intestinal stenosis: A case report.
    Liu A; Guo J; Liu H; Xu Y; Wu J; Mao T; Tian Z; Ding X
    Medicine (Baltimore); 2022 Oct; 101(42):e31213. PubMed ID: 36281114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japanese pediatric patient with moderately active ulcerative colitis successfully treated with ustekinumab: A case report.
    Kakiuchi T; Yoshiura M
    Medicine (Baltimore); 2022 Feb; 101(7):e28873. PubMed ID: 35363198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pouchitis showed complete response to ustekinumab].
    Nemoto Y; Tajima S; Saito K; Satoi A; Matsui T; Kimura S; Nakamura F
    Nihon Shokakibyo Gakkai Zasshi; 2024; 121(4):307-314. PubMed ID: 38599841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
    Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
    Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.
    Alsoud D; De Hertogh G; Compernolle G; Tops S; Sabino J; Ferrante M; Thomas D; Vermeire S; Verstockt B
    J Crohns Colitis; 2022 Nov; 16(10):1562-1570. PubMed ID: 35533353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Welty M; Mesana L; Padhiar A; Naessens D; Diels J; van Sanden S; Pacou M
    Curr Med Res Opin; 2020 Apr; 36(4):595-606. PubMed ID: 31960724
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab.
    Dai C; Huang YH
    Rev Esp Enferm Dig; 2024 Mar; 116(3):176-177. PubMed ID: 37314119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab Decreases Circulating Th17 Cells in Ulcerative Colitis.
    Imazu N; Torisu T; Ihara Y; Umeno J; Kawasaki K; Fujioka S; Fuyuno Y; Matsuno Y; Moriyama T; Kitazono T
    Intern Med; 2024 Jan; 63(2):153-158. PubMed ID: 37197955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials.
    Rolston VS; Kimmel J; Popov V; Bosworth BP; Hudesman D; Malter LB; Hong S; Chang S
    Dig Dis Sci; 2021 May; 66(5):1631-1638. PubMed ID: 32445049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report.
    Huang BB; Han LC; Liu GF; Lv XD; Gu GL; Li SQ; Chen L; Wang HQ; Zhan LL; Lv XP
    World J Gastroenterol; 2020 Dec; 26(46):7425-7435. PubMed ID: 33362394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Successful treatment of ulcerative colitis-related post-colectomy enteritis refractory to multiple therapies with ustekinumab.
    Guo C; He S; Wang H
    Front Immunol; 2024; 15():1297508. PubMed ID: 38433841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
    Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
    Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful use of infliximab and tacrolimus combination therapy in a patient with ulcerative colitis refractory to infliximab dose intensification plus azathioprine.
    Cortes X; Borrás-Blasco J; Fernendez S; Moreno M; Rodríguez J; Molés JR; Casterá E
    Int J Clin Pharmacol Ther; 2016 Feb; 54(2):125-8. PubMed ID: 26754306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature.
    Rao S; Viola A; Ksissa O; Fries W
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34667052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study.
    Matsuoka K; Nagano K; Nagasaki S; Murata Y; Hisamatsu T
    BMJ Open; 2022 May; 12(5):e060081. PubMed ID: 35508346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis.
    Morikubo H; Tojima R; Maeda T; Matsuoka K; Matsuura M; Miyoshi J; Tamura S; Hisamatsu T
    Sci Rep; 2024 Feb; 14(1):4386. PubMed ID: 38388662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
    Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.